February 7, 2011 โ€“ A rare and often underreported form of stroke involving veins instead of arteries is more common than previously thought, according to the American Heart Association's (AHA) first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

February 7, 2011 โ€“ Final testing for a point-of-care blood analyzer will begin at four hospitals in North America. The QL Care (QLCA) analyzer, by CardioGenics, tests for troponin-I levels, and data will be used to file a 510(k) application with the U.S. Food and Drug Administration (FDA).

February 4, 2011 โ€“ In the largest group of emergency department patients with atrial flutter studied to date, researchers found these patients may be substantially different from those described in the cardiology literature. The results of the study were published in the Annals of Emergency Medicine.

February 4, 2011 โ€“ More heart disease tests do not necessarily add up to a better diagnosis. According to a new practice guideline, a basic risk assessment that accounts for such factors as cholesterol level, blood pressure, age, sex, family history, smoking and diabetes is still the strongest tool a doctor can use in predicting the likelihood of heart disease.

February 4, 2011 โ€“ A new mobile radiology application cleared today by the U.S. Food and Drug Administration (FDA) will allow physicians to view and make a diagnosis from medical images on the Apple iPhone and iPad.

February 4, 2011 โ€“ Researchers at the National Institutes of Health's (NIH) Undiagnosed Diseases Program (UDP) have identified the genetic cause of a rare and debilitating vascular disorder not previously explained in the medical literature.

February 3, 2011 โ€“ Widespread screening or routine ultrasound for blocked neck arteries to determine stroke risk isn't necessary, according to new guidelines from the American Heart Association/American Stroke Association, American College of Cardiology and other groups.

February 3, 2011 โ€“ Behrman Capital, a private equity investment firm based in New York and San Francisco, has acquired Atherotech, a cardiometabolic testing services provider. Atherotech offers the VAP (Vertical Auto Profile) advanced lipid profile test.

February 1, 2011 โ€“ The U.S. Food and Drug Administration has approved a Phase I clinical trial to test a new technology for treating critical limb ischemia (CLI). The Investigational Device Exemption (IDE) allows Arteriocyte to test its Magellan MAR01 technology.

February 1, 2011 โ€“ Despite the benefits of therapy with implantable cardioverter-defibrillators (ICDs), inappropriate shocks from the devices are common and place patients at a greater mortality risk. These were the conclusions drawn by a Dutch research team that examined the incidence, predictors and patient outcomes of inappropriate ICD shocks in a large, real-world patient population.

Subscribe to
ยฉ Copyright Wainscot Media. All Rights Reserved.
Subscribe Now